Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bernink, P.J.L.M.
Right arrow Articles by Rogers, W.J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bernink, P.J.L.M.
Right arrow Articles by Rogers, W.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Issues in discharge therapy after hospitalization for UA/NSTEMI

P.J.L.M. Bernink*,1, M. Rather2, J.S. Hochman3 and W.J. Rogers4

1 Martini Hospital, Groningen, The Netherlands
2 Royal Brompton Hospital, London, U.K.
3 St. Luke's/Roosevelt Hospital and Columbia University, New York, New York, USA
4 University of Alabama Medical Center, Birmingham, Alabama, USA

* Correspondence: Peter J. L. M. Bernink, Martini Hospital, Groningen, The Netherlands.

Abstract

New treatment guidelines for the management of unstable angina and non-ST-segment elevation myocardial infarction were recently issued by the ACC/AHA and the ESC. Both sets of guidelines include recommendations for discharge therapies, and discuss the importance of aggressive risk management, as well as the use of medications, including aspirin, ß-blockers, lipid-lowering agents, and angiotensin-converting enzyme (ACE) inhibitors. These new recommendations were the subject of workshops held in September 2000, at the 4th Annual Experts' Meeting of the International Cardiology Forum. In general, workshop participants found the new ACC/AHA and ESC guidelines to be useful and consistent with practice. However, there were conflicting views on a number of topics, such as who should be treated with lipid-modifying medications, and whether the indications for ACE inhibitors should be expanded. The discussions also identified several areas of discharge management where more definitive trial data would be helpful. Some participants felt that the incremental benefit of individual agents in multidrug regimens has not yet been clearly established. There was also concern that, as the number of effective therapies increases, lack of patient compliance and financial constraints may impose greater limitations on guidelines implementation.

Key Words: Unstable angina • discharge therapy • guidelines • ACE inhibitors

References

  1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Unstable Angina). J Am Coll Cardiol. 2000;36:970–1062[Free Full Text]
  2. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. (chair)Eur Heart J. 2000;21:1406–1432[Free Full Text]
  3. Gottlieb S, Weisfeldt ML, Ouyang P, et al. Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: a randomised, double-blind, placebocontrolled trial. Circulation. 1986;73:331–337[Abstract/Free Full Text]
  4. Telford A, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet. 1981;1:1225–1228[Web of Science][Medline]
  5. Lubsen JTJ. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Inter-university Nifedipine/ metoprolol Trial (HINT). Am J Cardiol. 1987;60:18A–25A[CrossRef][Medline]
  6. Olsson G, Tuomilehto J, Berglund G, et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY Study. Am J Hypertens. 1991;4:151–158 (2 Pt 1)[Web of Science][Medline]
  7. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction? Arch Intern Med. 2000;160:947–952[Abstract/Free Full Text]
  8. Adult Cardiac Surgery National Database. Chicago IL: Society of Thoracic Surgeons.
  9. The RISC group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827–830[CrossRef][Web of Science][Medline]
  10. The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996;348:1329–1339[CrossRef][Web of Science][Medline]
  11. CURE Study Investigators. The clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme. Eur Heart J. 2000;21:2033–2041[Abstract/Free Full Text]
  12. Fragmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Long-term lowmolecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:701–707[CrossRef][Web of Science][Medline]
  13. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001–1009[Abstract/Free Full Text]
  14. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary artery disease and a broad range of initial cholesterol levels. N Engl J Med; 339: 1349–1357.
  15. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–418[Abstract/Free Full Text]
  16. HOPE Investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med. 2000;342:145–153[Abstract/Free Full Text]
  17. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement study. The SAVE Investigators. N Engl J Med. 1992;327:669–677[Abstract]
  18. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302[Abstract]
  19. Pfeffer MA, Domanski M, Rosenberg Y, et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin Converting Enzyme Inhibition. Am J Cardiol. 1998;82:25H–30H[Web of Science][Medline]
  20. Yusuf S, Lonn E. Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing trials. Eur Heart J. 1998;19(Suppl J):36–44
  21. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986[Abstract/Free Full Text]
  22. Stratton IM, Adler AI, Neil HA, Matthews DR, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412[Abstract/Free Full Text]
  23. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57–65[Abstract]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bernink, P.J.L.M.
Right arrow Articles by Rogers, W.J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bernink, P.J.L.M.
Right arrow Articles by Rogers, W.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?